Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 7/20 | 0.55 |
| ▸ | DRD1 | P21728 | 7/20 | 0.55 |
| ▸ | DRD5 | P21918 | 7/20 | 0.55 |
| ▸ | DRD3 | P35462 | 7/20 | 0.55 |
| ▸ | DRD4 | P21917 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903663 | 0.87 | DRD1 (0.68) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL12595448 | 0.87 | — | — | |
| SCHEMBL6907774 | 0.87 | DRD1 (0.68) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL227363 | 0.86 | CYP1A2 (0.60) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL43307 | 0.86 | METAP1 (0.53) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL29940518 | 0.86 | METAP1 (0.53) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL12077840 | 0.85 | METAP1 (0.51) | METAP1DRD2DRD1DRD5DRD3 | |
| Ammonia Solution, Strong SCHEMBL1799116 | 0.85 | DRD1 (0.66) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL3813236 | 0.83 | DRD1 (0.52) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL228868 | 0.83 | DRD1 (0.56) | METAP1DRD2DRD1DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116239561-B | Benzofluorene photochromic compound and application thereof | 上海甘田光学材料有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-116239561-A | Benzofluorene photochromic compound and application thereof | 上海甘田光学材料有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11578077-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200039997-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10479796-B2 | Spiro-oxazolones | HOFFMAN-LA ROCHE INC. (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3083633-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-3083633-A1 | SPIRO-OXAZOLONES | F.HOFFMANN-LA ROCHE AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| EP-0861837-B1 | 2-Aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-04-28 | — | — | EP | disclosed |
| EP-1409468-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6638927-B2 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl) -ethyl)-benzamide for example | CHIRON CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-20030199499-A1 | Novel guanidinobenzamides | CHIRON CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002018327-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| US-5968954-A | EXHIBIT SELECTIVE BINDING AFFINITY FOR 5-HYDROXYTRYPTAMINE RECEPTORS | ADIR ET COMPAGNIE (FR) | 1999-10-19 | — | — | US | disclosed |
| CN-1218051-A | New 2,3-dioxide, indanol compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-06-02 | — | — | CN | disclosed |
| EP-0861837-A1 | 2-Aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-09-02 | — | — | EP | disclosed |
| US-4975461-A | Enzymes/oxidoreductases/inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1990-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578077-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | METAP1 4200/4885DRD2 46/4885DRD1 26/4885 |
| US-20030199499-A1 | Novel guanidinobenzamides | GUCY1B2, GPR119, GUCY1B1 | METAP1 2959/4885DRD2 710/4885DRD1 1131/4885 |
| US-20200039997-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | METAP1 4200/4885DRD2 46/4885DRD1 26/4885 |
| US-20170008901-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | METAP1 4200/4885DRD2 46/4885DRD1 26/4885 |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | MC4R, MC5R, MC3R | METAP1 717/4885DRD2 198/4885DRD1 230/4885 |
| US-10479796-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | METAP1 4200/4885DRD2 46/4885DRD1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.